Search Results
Results found for "Novo Nordisk Foundation"
- Ben Clements on Rescuing Opioids with GPCR Modulators
His work highlights how foundational GPCR science can drive therapeutic innovation.
- The Truth About GPCR Product Launches: Years in the Making
Exploring the foundational stages of scientific breakthroughs with Eric Trinquet, highlighting that true It reflects decades of foundational R&D—from the fluorescent probes of Cisbio’s early days to the receptor-targeting
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
This collaboration would become the foundation of a GPCR imaging breakthrough that neither of them anticipated excitable tissues and reveal mechanisms driving hormone secretion.That shift in perspective became foundational
- Understanding Orthosteric Binding: The Key to Drug Action
This foundational knowledge guides researchers in the development of new therapeutics.
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
Mark: “Have you found this to be accurate?” Beth: “Yes. Top candidates will have a solid foundation in GPCR pharmacology as well as some experience in drug discovery
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
The research team, led by Brandon Novy and colleagues, utilized an innovative APEX2/AUR biosensor that
- Exscientia is 10 years old this July!
Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design of patients with advanced haematological cancers, international partnerships with pharma and healthcare foundations
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
modulation of isoform- and ligand specific aGPCR functions using unique tools, and thus establishes a foundation
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
They’re cracks in the foundation. And cracks don’t stay small for long.
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
While AlphaFold provides an excellent foundation for generating hypotheses in drug discovery, it is not
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
In the experiment, similar sets of residues were found to be in significant contact with both ligands Our results build a strong foundation for further improvement of our approach by rationalizing the kinetics
- Reflections on My PhD Journey: Lessons Learned
The right environment, paired with a supportive supervisor, laid the foundation for a fulfilling and Analyze Your Work as You Go The PhD journey is often compared to a rollercoaster, and I found this to
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
GPCR imaging is evolving from a specialized technique into a foundational method for receptor biology
- Understanding the Journey: Catherine Demery's Path to Addiction Science
She found herself drawn toward the science behind the drugs, rather than their clinical application. Catherine’s methodical retention of those skills later gave her a solid foundation in her academic work
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
molecular determinants of ligand efficacy and potency in GPCR signalling, this research provides a foundation
- Your GPCR Program Decisions Depend on Good Data Interpretation
excellence His approach didn’t just create a productive lab—it accelerated outcomes and laid the cultural foundation
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
Catherine’s work lays the foundation for designing better interventions, from preclinical models to clinical
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder The company's co-founder, GPCR pioneer and Nobel laureate Robert Lefkowitz, M.D., has 50 years of experience
- Deficiency of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in ...
protein-coupled receptors (GPCRs) and it participates in inflammatory and immune responses that have been found In vivo, we found that inhibition of GRP78-ATF6-CHOP apoptosis signaling improved ESS symptoms, and the This research further clarified the underlying role of β-arrestin2 and provided an experimental foundation
- From Lab Bench to Boardroom: The Unexpected Path of a Medicinal Chemist
GPCR Podcast, she shares how her background in medicinal chemistry paved the way to co-founding Celtarys However, as she and her co-founders soon realized, commercializing it was the only way to deliver that
- 📰 GPCR Weekly News, February 13 to 19, 2023
Hauser on receiving 4.8 mill DKK from Carlsberg Foundation’s Semper Ardens: Accelerate programme.
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Clark , laid the foundation for today’s quantitative pharmacology.
- 📰 GPCR Weekly News, April 24 to 30, 2023
LSX World Congress Novel living yeast-based dual biosensor for detecting peptide variants The Galien Foundation
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
Early optimization prevents later variability and sets the foundation for scalable screening. 2.
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
. 🌟 Speaker Spotlight In the run-up to the conference, our founder Yamina Berchiche is speaking with At Yamina's Corner , our founder Yamina Berchiche works closely with organizations to help them navigate
- Targeting Intracellular Allosteric Sites in GPCRs
understanding of GPCR biased signaling induced by intracellular allosteric agonists and establish a strong foundation
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
The physical barrier this lipid bilayer creates is dynamic and interactive, becoming the foundation for
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
Yamina Berchiche , Founder and CEO of Dr. GPCR.

















